Karuna Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $654,000 | $10.6M | $37.0M | $0 | — | — |
| Operating income | −$494.8M | −$289.7M | −$143.9M | −$71.8M | −$45.4M | −$14.5M |
| Net income | −$433.7M | −$276.3M | −$143.8M | −$68.6M | −$44.0M | −$17.5M |
| Total assets | $1.34B | $1.16B | $527.7M | $347.6M | $393.0M | $15.9M |
| Total liabilities | $82.0M | $37.1M | $25.6M | $8.7M | $3.1M | $3.8M |
| Equity | $1.25B | $1.13B | $502.0M | $338.9M | $389.9M | −$29.9M |
| EPS (diluted) | $-11.73 | $-8.74 | $-4.94 | $-2.59 | — | — |
| Shares out. | 34.5M | 29.8M | 27.0M | 26.1M | 26.0M | 12 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −75654.0%
- Net margin
- −66311.9%
- Return on equity
- −34.6%
- Return on assets
- −32.5%
- Return on capital (ROCE)
- −39.0%
- Liabilities / assets
- 6.1%
- Debt / equity
- 0.07×
- Book value / share
- $36.34
- Revenue growth (YoY)
- −93.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 17.27safe
- Accruals / assets
- −3.6%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-03-19An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
- Phase 1Recruitingreadout ~2026-04-05A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
- Phase 3Recruitingreadout ~2026-10-05A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Phase 3Recruitingreadout ~2026-11-24A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 1Recruitingreadout ~2026-12-03A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
- Phase 3Recruitingreadout ~2026-12-09A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Phase 3Recruitingreadout ~2027-09-07Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Phase 4Recruitingreadout ~2027-11-30KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMar 18, 2024
- Other material eventMar 14, 2024
- Shareholder voteMar 12, 2024
- Other material eventMar 1, 2024
- Results of operationsFeb 22, 2024
- Director / officer change · Other material eventJan 16, 2024
- Entered a material agreement · Director / officer changeDec 22, 2023
- Other material eventDec 22, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.